EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differing natural killer cell, T cell and antibody profiles in antiretroviral-naive HIV-1 viraemic controllers with and without protective HLA alleles

Ana Moyano, Bongiwe Ndlovu, Msizi Mbele, Kewreshini Naidoo, Nasreen Khan, Jaclyn K Mann iD, Thumbi Ndung'u iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0286507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Ana Moyano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Africa Health Research Institute, KwaZulu-Natal, South Africa, Durban, South Africa. Hauptthemen laut MEDLINE: HIV-1, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, National Research Foundation Thuthuka, National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous work suggests that HIV controllers with protective human leukocyte antigen class I alleles (VC+) possess a high breadth of Gag-specific CD8+ T cell responses, while controllers without protective alleles (VC-) have a different unknown mechanism of control. We aimed to gain further insight into potential mechanisms of control in VC+ and VC-. We studied 15 VC+, 12 VC- and 4 healthy uninfected individuals (UI). CD8+ T cell responses were measured by ELISpot. Flow cytometry was performed to analyse surface markers for activation, maturation, and exhaustion on natural killer (NK) cell and T cells, as well as cytokine secretion from stimulated NK cells. We measured plasma neutralization activity against a panel of 18 Env-pseudotyped viruses using the TZM-bl neutralization assay. We found no significant differences in the magnitude and breadth of CD8+ T cell responses between VC+ and VC-. However, NK cells from VC- had higher levels of activation markers (HLA-DR and CD38) (p = 0.03), and lower cytokine expression (MIP-1β and TNF-α) (p = 0.05 and p = 0.04, respectively) than NK cells from VC+. T cells from VC- had higher levels of activation (CD38 and HLA-DR co-expression) (p = 0.05), as well as a trend towards higher expression of the terminal differentiation marker CD57 (p = 0.09) when compared to VC+. There was no difference in overall neutralization breadth between VC+ and VC- groups, although there was a trend for higher neutralization potency in the VC- group (p = 0.09). Altogether, these results suggest that VC- have a more activated NK cell profile with lower cytokine expression, and a more terminally differentiated and activated T cell profile than VC+. VC- also showed a trend of more potent neutralizing antibody responses that may enhance viral clearance. Further studies are required to understand how these NK, T cell and antibody profiles may contribute to differing mechanisms of control in VC+ and VC-.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHumansHIV Non-ProgressorsAllelesCD8-Positive T-LymphocytesKiller Cells, NaturalHLA-DR AntigensCytokines

Substanzen

HLA-DR AntigensCytokines

Autor:innen und Institutionen

  • Africa Health Research Institute, KwaZulu-Natal, South Africa, Durban, South Africa.
  • HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Division of Infection and Immunity, University College London, London, United Kingdom.
  • Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, United States of America.

ORCID-Profile: Jaclyn K Mann, Thumbi Ndung'u

Förderung

  • Wellcome Trust
  • National Research Foundation Thuthuka
  • National Research Foundation
  • International AIDS Vaccine Initiative
  • Victor Daitz Foundation
  • UK Foreign, Commonwealth & Development Office

Zitieren

APA

Moyano, A., Ndlovu, B., Mbele, M., Naidoo, K., Khan, N., Mann, J. K., & Ndung'u, T. (2023). Differing natural killer cell, T cell and antibody profiles in antiretroviral-naive HIV-1 viraemic controllers with and without protective HLA alleles. PLOS ONE. https://doi.org/10.1371/journal.pone.0286507

Vancouver

Moyano A, Ndlovu B, Mbele M, Naidoo K, Khan N, Mann JK, et al. Differing natural killer cell, T cell and antibody profiles in antiretroviral-naive HIV-1 viraemic controllers with and without protective HLA alleles. PLOS ONE. 2023. doi:10.1371/journal.pone.0286507

BibTeX
@article{Moyano2023,
  author = {Moyano, Ana and Ndlovu, Bongiwe and Mbele, Msizi and Naidoo, Kewreshini and Khan, Nasreen and Mann, Jaclyn K and Ndung'u, Thumbi},
  title = {Differing natural killer cell, T cell and antibody profiles in antiretroviral-naive HIV-1 viraemic controllers with and without protective HLA alleles},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0286507}
}
Kostenlos starten →